Piper Sandler lowered the firm’s price target on Adaptive Biotechnologies to $5 from $6 and keeps an Overweight rating on the shares following quarterly results. The firm’s change in price target primarily reflects its decreased near-term revenue growth rate.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ADPT:
- Adaptive Biotechnologies sees FY24 operating expenses $360M-$370M
- Adaptive Biotechnologies reports Q4 EPS (48c), consensus (33c)
- Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results
- Adaptive Biotechnologies (ADPT) Q4 Earnings Cheat Sheet
- Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 14, 2024
